针对性护理干预在非小细胞肺癌胸腔镜手术患者中的应用研究
|
摘要
目的探讨对非小细胞肺癌胸腔镜手术患者给予针对性护理干预后获得的临床效果。方法选择我院2015年7月～2018年3月收治的94例非小细胞肺癌患者作为研究对象;抽签法分组后明确胸腔镜手术期间各组护理方式,对照组47例给予传统护理,观察组47例给予传统护理+针对性护理;比较两组手术护理结果。结果观察组FEV1、FVC以及FEV1/FVC分别为(1.73±0.45)L、(65.59±13.53)L和(61.06±13.42)%,对照组分别为(1.36±0.29)L、(54.13±12.43)L和(51.39±12.29)%,观察组患者肺功能指标明显高于对照组,差异有统计学意义(P<0.05);观察组的并发症发生率为2.13%,明显低于对照组的25.53%,差异有统计学意义(P<0.05);观察组社会功能、心理功能、躯体功能以及生活状态评分分别为(31.55±0.61)分、(35.55±4.59)分、(47.61±1.53)分以及(19.59±0.76)分,对照组分别为(28.89±0.06)分、(25.69±4.06)分、(40.31±1.29)分以及(15.43±1.51)分,观察组生活质量各项评分均明显高于对照组(P<0.05)。结论临床对非小细胞肺癌患者在实施胸腔镜手术期间,针对性护理干预措施的采用,在肺功能改善、并发症减少以及生活质量提升方面,效果确切,可对患者预后能力提升以及病情快速好转奠定基础,充分表明针对性护理应用的可行性。
Objective To explore the clinical effects of targeted nursing intervention in patients undergoing thoracoscopic surgery for non-small cell lung cancer. Methods 94 patients with non-small cell lung cancer admitted to our hospital from July 2015 to March 2018 were selected as experimental subjects. The control group(47 cases) were given traditional care; the observation group(47 cases) were given traditional care + targeted care. The surgical care results were compared between the two groups. Results The FEV1, FVC and FEV1/FVC of the observation group were(1.73±0.45) L,(65.59±13.53) L and(61.06±13.42) %, respectively, and(1.36±0.29) L,(54.13±12.43) L and(51.39±12.29) % in the control group. The lung function index of the observation group was significantly higher than that of the control group(P<0.05). The complication rate of the observation group was 2.13%, which was significantly lower than that of the con trol group(25.53%)(P<0.05). The social function, psychological function, physical function and living status scores of the observation group were(31.55 ±0.61),(35.55 ±4.59),(47.61 ±1.53) and(19.59 ±0.76), respectively, which were(28.89 ±0.06),(25.69±4.06),(40.31±1.29) and(15.43±1.51) in the control group. The scores of quality of life in the observation group were significantly higher than those in the control group(P<0.05). Conclusion During the implementation of thoracoscopic surgery in patients with non-small cell lung cancer, the use of targeted nursing interventions can clearly improve lung function, reduce complications, improve quality of life, and lay the foundation for improving patients' prognosis and rapid improvement of the conditions, which fully demonstrate the feasibility of targeted nursing intervention.
Objective To explore the clinical effects of targeted nursing intervention in patients undergoing thoracoscopic surgery for non-small cell lung cancer. Methods 94 patients with non-small cell lung cancer admitted to our hospital from July 2015 to March 2018 were selected as experimental subjects. The control group(47 cases) were given traditional care; the observation group(47 cases) were given traditional care + targeted care. The surgical care results were compared between the two groups. Results The FEV1, FVC and FEV1/FVC of the observation group were(1.73±0.45) L,(65.59±13.53) L and(61.06±13.42) %, respectively, and(1.36±0.29) L,(54.13±12.43) L and(51.39±12.29) % in the control group. The lung function index of the observation group was significantly higher than that of the control group(P<0.05). The complication rate of the observation group was 2.13%, which was significantly lower than that of the con trol group(25.53%)(P<0.05). The social function, psychological function, physical function and living status scores of the observation group were(31.55 ±0.61),(35.55 ±4.59),(47.61 ±1.53) and(19.59 ±0.76), respectively, which were(28.89 ±0.06),(25.69±4.06),(40.31±1.29) and(15.43±1.51) in the control group. The scores of quality of life in the observation group were significantly higher than those in the control group(P<0.05). Conclusion During the implementation of thoracoscopic surgery in patients with non-small cell lung cancer, the use of targeted nursing interventions can clearly improve lung function, reduce complications, improve quality of life, and lay the foundation for improving patients' prognosis and rapid improvement of the conditions, which fully demonstrate the feasibility of targeted nursing intervention.
引文
[1]金德芹.针对性护理干预对非小细胞肺癌胸腔镜手术患者的影响[J].齐鲁护理杂志,2014,20(10):29-31.
[2]Chang JY,Senan S,Paul MA,et al.Stereotactic ablative radiotherapy versus lobectomy for operable stage I nonsmall-cell lung cancer:A pooled analysis of two randomised trials[J].The Lancet Oncology,2015,16(9):124-126.
[3]王霞.胸腔镜辅助下肺癌根治术与常规开胸手术治疗非小细胞肺癌的疗效对比及护理研究[J].国际护理学杂志,2015,19(9):1286-1289.
[4]Brahmer J,Reckamp KL,Baas P,et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J].New England Journal of Medicine,2015,373(2):123-135.
[5]Chang JY,Senan S,Paul MA,et al.Stereotactic ablative radiotherapy versus lobectomy for operable stage I nonsmall-cell lung cancer:A pooled analysis of two randomised trials[J].The Lancet Oncology,2015,16(6):630-637.
[6]杜鹃.针对性护理干预对非小细胞肺癌胸腔镜手术患者的影响[J].航空航天医学杂志,2017,13(12):1535-1536.
[7]Zhai R,Yu X,Shafer A,et al.The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection[J].Chest,2014,145(2):346-353.
[8]马景华,朱冰,严磊,等.传统开胸手术和电视胸腔镜治疗早期非小细胞肺癌老年患者的疗效比较[J].实用临床医药杂志,2017,21(13):211-213.
[9]Gonzalez-Rivas D,Fieira E,Delgado M,et al.Is uniportal thoracoscopic surgery a feasible approach for advanced stages of non-small cell lung cancer?[J].Journal of Thoracic Disease,2014,6(6):641.
[10]Gerber DE,Urbanic JJ,Langer C,et al.Treatment design and rationale for a randomized trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small-cell lung cancer(RTOG 3505)[J].Clinical lung cancer,2017,18(3):333-339.
[11]马景华,朱冰,严磊,等.传统开胸手术和电视胸腔镜治疗早期非小细胞肺癌老年患者的疗效比较[J].实用临床医药杂志,2017,21(13):211-213.
[12]LabbéC,Anderson M,Simard S,et al.Wait times for diagnosis and treatment of lung cancer:A single-centre experience[J].Current Oncology,2017,24(6):367.
[13]李晓辉,于共荣,陈秀秀,等.非小细胞肺癌合并胸椎转移瘤1例临床护理[J].齐鲁护理杂志,2017,23(8):109-110.
[14]沈慧敏,鲁继斌.延续性护理对非小细胞肺癌化疗患者近期复发及生存质量的影响[J].中国医药导报,2017,14(28):166-169.
[15]LabbéC,Anderson M,Simard S,et al.Wait times for diagnosis and treatment of lung cancer:A single-centre experience[J].Current Oncology,2017,24(6):367.
[16]Xuan LZ,Shu-Chan C,Wen-Tsung H.P1.10-006 adverse events after first-line target therapy for non-small cell lung cancer patients in a case management model[J].Journal of Thoracic Oncology,2017,12(11):S2024-S2025.
[17]杨扬,李喆,许瑞彬,等.完全胸腔镜下与开胸肺癌根治术治疗非小细胞肺癌的临床比较[J].实用临床医药杂志,2015,19(11):46-49.
[18]Vijayvergia N,Shah PC,Denlinger CS.Survivorship in non-small cell lung cancer:Challenges faced and steps forward[J].Journal of the National Comprehensive Cancer Network,2015,13(9):1151-1161.
[19]喻园园,邓小琴,刘平.儿童胸部MRI检查心理护理干预探讨[J].中华肺部疾病杂志(电子版),2016,9(2):236-237.
[20]Dalal A A,Guerin A,Mutebi A,et al.Treatment patterns,clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib:A retrospective observational claims analysis[J].Journal of Drug Assessment,2018,7(1):21-27.
[2]Chang JY,Senan S,Paul MA,et al.Stereotactic ablative radiotherapy versus lobectomy for operable stage I nonsmall-cell lung cancer:A pooled analysis of two randomised trials[J].The Lancet Oncology,2015,16(9):124-126.
[3]王霞.胸腔镜辅助下肺癌根治术与常规开胸手术治疗非小细胞肺癌的疗效对比及护理研究[J].国际护理学杂志,2015,19(9):1286-1289.
[4]Brahmer J,Reckamp KL,Baas P,et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J].New England Journal of Medicine,2015,373(2):123-135.
[5]Chang JY,Senan S,Paul MA,et al.Stereotactic ablative radiotherapy versus lobectomy for operable stage I nonsmall-cell lung cancer:A pooled analysis of two randomised trials[J].The Lancet Oncology,2015,16(6):630-637.
[6]杜鹃.针对性护理干预对非小细胞肺癌胸腔镜手术患者的影响[J].航空航天医学杂志,2017,13(12):1535-1536.
[7]Zhai R,Yu X,Shafer A,et al.The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection[J].Chest,2014,145(2):346-353.
[8]马景华,朱冰,严磊,等.传统开胸手术和电视胸腔镜治疗早期非小细胞肺癌老年患者的疗效比较[J].实用临床医药杂志,2017,21(13):211-213.
[9]Gonzalez-Rivas D,Fieira E,Delgado M,et al.Is uniportal thoracoscopic surgery a feasible approach for advanced stages of non-small cell lung cancer?[J].Journal of Thoracic Disease,2014,6(6):641.
[10]Gerber DE,Urbanic JJ,Langer C,et al.Treatment design and rationale for a randomized trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small-cell lung cancer(RTOG 3505)[J].Clinical lung cancer,2017,18(3):333-339.
[11]马景华,朱冰,严磊,等.传统开胸手术和电视胸腔镜治疗早期非小细胞肺癌老年患者的疗效比较[J].实用临床医药杂志,2017,21(13):211-213.
[12]LabbéC,Anderson M,Simard S,et al.Wait times for diagnosis and treatment of lung cancer:A single-centre experience[J].Current Oncology,2017,24(6):367.
[13]李晓辉,于共荣,陈秀秀,等.非小细胞肺癌合并胸椎转移瘤1例临床护理[J].齐鲁护理杂志,2017,23(8):109-110.
[14]沈慧敏,鲁继斌.延续性护理对非小细胞肺癌化疗患者近期复发及生存质量的影响[J].中国医药导报,2017,14(28):166-169.
[15]LabbéC,Anderson M,Simard S,et al.Wait times for diagnosis and treatment of lung cancer:A single-centre experience[J].Current Oncology,2017,24(6):367.
[16]Xuan LZ,Shu-Chan C,Wen-Tsung H.P1.10-006 adverse events after first-line target therapy for non-small cell lung cancer patients in a case management model[J].Journal of Thoracic Oncology,2017,12(11):S2024-S2025.
[17]杨扬,李喆,许瑞彬,等.完全胸腔镜下与开胸肺癌根治术治疗非小细胞肺癌的临床比较[J].实用临床医药杂志,2015,19(11):46-49.
[18]Vijayvergia N,Shah PC,Denlinger CS.Survivorship in non-small cell lung cancer:Challenges faced and steps forward[J].Journal of the National Comprehensive Cancer Network,2015,13(9):1151-1161.
[19]喻园园,邓小琴,刘平.儿童胸部MRI检查心理护理干预探讨[J].中华肺部疾病杂志(电子版),2016,9(2):236-237.
[20]Dalal A A,Guerin A,Mutebi A,et al.Treatment patterns,clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib:A retrospective observational claims analysis[J].Journal of Drug Assessment,2018,7(1):21-27.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |